Skip to content

2026 Publications

  • Tonutti A, Motta F, Moschetti L, Bruni C, Mihai C, Iannone C, Pellico MR, Stano S, Erba S, Barison C, Pazzi E, Benini A, Moccaldi B, Dávid KJ, Ágoston-Szabó Á, Gabrielli B, Nava F, Tari D, Ciommo FRD, Sasaki Y, Boleto G, Bečvář R, Brigante A, Maurer B, Limonta M, Elziaty RA, Atzeni F, Núñez LML, Foti R, Benvenuti F, Granel B, Rezus E, Caillault L, Blaise S, Sieiro Santos C, Cacciapaglia F, Giacomelli R, De Angelis R, Guiducci S, Temiz Karadag D, Szűcs G, Idolazzi L, Kumánovics G, Iannone F, Cutolo M, Moroncini G, Riccieri V, Del Papa N, Zanatta E, Distler O, Kuwana M, Selmi C, De Santis M. Cancer in systemic sclerosis: clinical associations and prognostic impact from the EUSTAR registry. Arthritis Rheumatol. 2026 Aug 28. doi: 10.1002/art.70303. Epub ahead of print. PMID: 42663235.

  • Di Donato S, Truchetet ME, Minerba M, Distler O, Alegre Sancho JJ, Braun-Moscovici Y, Bergmann C, Sfikakis P, de Vries-Bouwstra JK, Baron M, Bellando-Randone S, Dagna L, Denton CP, Vonk MC, Smith V, Castellvi I, Riemekasten G, Balanescu A, Kuwana M, De Santis M, Solanki K, Batalov A, Mukuchyan V, Matucci-Cerinic M, Allanore Y, Del Galdo F, Hughes M; EUSTAR Collaborators. Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort. Arthritis Care Res (Hoboken). 2026 Jun 15. doi: 10.1002/acr.80100. Epub ahead of print. PMID: 42294821. (PDF)

  • Avanoglu-Guler A, Hughes M, De Luca G, Bellando Randone S, Launay D, Wojteczek A, Rednic S, Chatelus E, Balbir-Gurman A, Moschetti L, Müller-Ladner U, Sfikakis PP, Idolazzi L, Papa ND, Distler O, Dagna L, Truchetet ME, Vonk MC, Del Galdo F, Matucci-Cerinic M, Campochiaro C; for EUSTAR Collaborators. Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database. Rheumatology (Oxford). 2026 May 5;65(5):keag176. doi: 10.1093/rheumatology/keag176. PMID: 41949854.

  • Burja B, Boubaya M, Bruni C, Christ L, Ananyeva LP, Atzeni F, Bergmann C, Carreira PE, De Vries-Bouwstra J, Papa ND, Marcoccia A, Masado O, Riemekasten G, Rosato E, Schmeiser T, Sprecher M, Hoffmann-Vold AM, Kollert F, Guler S, Distler O, Elhai M; EUSTAR collaborators. Anti-Ro/SSA and rheumatoid factor antibodies are associated with more severe lung involvement in patients with systemic sclerosis: a study from the EUSTAR database. Eur J Intern Med. 2026 May 26:106898. doi: 10.1016/j.ejim.2026.106898. Epub ahead of print. PMID: 42191555. (PDF)

  • Käs F, Elhai M, Becker MO, Dobrota R, Mihai C, Sauer G, Tofani L, Bečvář R, Rednic S, Carreira PE, Kumánovics G, Airò P, Mueller-Ladner U, Del Galdo F, Ramazan AM, Martin M, Simeón-Aznar CP, Parvu M, Del Papa N, Hoffmann-Vold AM, Distler O, Bruni C; EUSTAR collaborators. Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database. J Autoimmun. 2026 May;160:103555. doi: 10.1016/j.jaut.2026.103555. Epub 2026 Apr 20. PMID: 42013635. (PDF)

  • Pecher AC, Boubaya M, Allanore Y, Smith V, de Vries-Bouwstra J, Bečvář R, Moroncini G, Launay D, De Santis M, Solanki K, Montecucco C, Idolazzi L, Nihal F, Przemyslaw K, Truchetet ME, Kuwana M, Del Gado F, Distler O, Elhai M, Henes J. Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score. Ann Rheum Dis. 2026 Mar 16:S0003-4967(26)00065-8. doi: 10.1016/j.ard.2026.01.016. Epub ahead of print. PMID: 41846198. (PDF)

  • Moschetti L, Rovaris S, Bonomi F, Codes-Mendez H, Martín-López M, Cacciapaglia F, Tonutti A, Galdo FD, Campochiaro C, Truchetet ME, Allanore Y, Kuwana M, Bruni C, Santos CS, Moroncini G, Caetano J, Granel B, Groseanu L, Pedretti E, Colombo E, Guerini M, Pereira Silva M, Bearzi P, Belloli L, Alegre-Sancho JJ, Maglio C, Cuomo G, Parvu M, Poormoghim H, Idolazzi L, Andréasson K, De Santis M, Iannone F, Carreira PE, Castellví I, Guiducci S, Cavazzana I, Franceschini F, Airò P, Lazzaroni MG. The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort. Ther Adv Musculoskelet Dis. 2026 Mar 2;18:1759720X261422369. doi: 10.1177/1759720X261422369. PMID: 41782907; PMCID: PMC12953999. (PDF)

  • Petelytska L, Tofani L, Velauthapillai A, Dobrota R, Becker MO, Mihai C, Muraru S, Elhai M, Jordan S, Hachulla E, Müller-Ladner U, Siegert E, Allanore Y, Riemekasten G, Bergmann C, Becvar R, Solanki K, Anic B, Szabo I, Stamenkovic B, Distler J, Carreira PE, Cuomo G, Castellví I, Balbir-Gurman A, Airò P, Litinsky I, Saketkoo LA, Bertaccini B, Vonk MC, de Vries-Bouwstra J, Hoffmann-Vold AM, Matucci-Cerinic M, Distler O, Bruni C; EUSTAR collaborators. The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133). Ann Rheum Dis. 2026 Jan 17:S0003-4967(25)04602-3. doi: 10.1016/j.ard.2025.12.008. Epub ahead of print. PMID: 41549016. (PDF)

  • Campochiaro C, Truchetet ME, Vonk M, De Luca G, Cuomo G, Ananieva LP, Hachulla E, Smith V, Gheorghiu AM, Becvar R, Carreira P, Hunzelmann N, Furst DE, Ortiz-Santamaria V, Del Galdo F, Matucci-Cerinic M, Hoffmann-Vold AM; EUSTAR collaborators. Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database. Arthritis Rheumatol. 2026 Jan 22. doi: 10.1002/art.70043. Epub ahead of print. PMID: 41568546. (PDF)